HighTower Advisors LLC Sells 84,770 Shares of Haleon PLC Sponsored ADR $HLN

HighTower Advisors LLC lowered its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 37.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 140,637 shares of the company’s stock after selling 84,770 shares during the quarter. HighTower Advisors LLC’s holdings in Haleon were worth $1,422,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Envestnet Portfolio Solutions Inc. boosted its holdings in Haleon by 2.3% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 63,726 shares of the company’s stock worth $644,000 after buying an additional 1,431 shares during the last quarter. TD Private Client Wealth LLC boosted its holdings in Haleon by 16.3% during the fourth quarter. TD Private Client Wealth LLC now owns 24,965 shares of the company’s stock worth $252,000 after buying an additional 3,505 shares during the last quarter. May Hill Capital LLC grew its stake in Haleon by 163.6% in the fourth quarter. May Hill Capital LLC now owns 27,494 shares of the company’s stock valued at $278,000 after acquiring an additional 17,063 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in Haleon by 7,738.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,448,724 shares of the company’s stock valued at $14,647,000 after acquiring an additional 1,430,242 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich grew its stake in Haleon by 3.6% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,457,159 shares of the company’s stock valued at $45,062,000 after acquiring an additional 153,530 shares during the period. Institutional investors own 6.67% of the company’s stock.

Haleon Trading Up 0.2%

NYSE:HLN opened at $8.72 on Thursday. Haleon PLC Sponsored ADR has a fifty-two week low of $8.65 and a fifty-two week high of $11.28. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The stock has a market capitalization of $38.61 billion, a PE ratio of 22.35, a price-to-earnings-growth ratio of 1.98 and a beta of 0.13. The business’s 50-day simple moving average is $9.45 and its 200-day simple moving average is $9.94.

Haleon (NYSE:HLN) last released its quarterly earnings data on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The business had revenue of $3.65 billion for the quarter. Sell-side analysts expect that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HLN has been the topic of several recent analyst reports. Argus upgraded Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Finally, Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.